Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.41 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297383 | 0.89 | GBA1 (0.40) | GBA1SPHK2SPHK1MAPK1SMN1; SMN2 | |
| SCHEMBL14413940 | 0.89 | GBA1 (0.40) | GBA1SPHK2SPHK1MAPK1SMN1; SMN2 | |
| SCHEMBL24670890 | 0.83 | GBA1 (0.48) | GBA1SPHK2SPHK1MAPK1 | |
| SCHEMBL11322928 | 0.83 | GBA1 (0.46) | GBA1GJB2SPHK2SPHK1MAPK1 | |
| SCHEMBL24177516 | 0.83 | GBA1 (0.48) | GBA1SPHK2SPHK1MAPK1 | |
| SCHEMBL31236147 | 0.83 | GBA1 (0.48) | GBA1SPHK2SPHK1MAPK1 | |
| SCHEMBL13083168 | 0.83 | GBA1 (0.44) | GBA1SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL16508369 | 0.83 | GBA1 (0.44) | GBA1SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL16248055 | 0.83 | GBA1 (0.44) | GBA1SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL14554176 | 0.83 | GBA1 (0.44) | GBA1SPHK2SPHK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130011421-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011421-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | LSS, CYP51A1, TLR7 | GBA1 261/4885GJB2 4428/4885SPHK2 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.